First projects of £3m UK fund for asbestos disease R&D reflect unmet medtech needs
This article was originally published in Clinica
The British Lung Foundation (BLF) has announced the first recipients of a £3m ($4.7m) three-year fund for asbestos-related disease (ARD) research and awareness-raising projects. Of the £1m per year that the BLF will disburse, at least £850,000 will be spent on research.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.